Search

Displaying results 8071 - 8080 of 10000 in total
  1. Drug

    Atipamezole

    go.drugbank.com/drugs/DB11481
    InvestigationalVet approved

    It has also been undergone research as a potential anti-Parkinsonian drug for humans. … Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.

  2. Drug

    Trestolone acetate

    go.drugbank.com/drugs/DB13958
    Experimental

    Trestolone acetate is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was never marketed. … It is an androgen ester – specifically, the C17 acetate ester of [DB05830].

  3. Drug

    Equilenin

    go.drugbank.com/drugs/DB03515
    Experimental

    Equilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.

  4. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

    Synonyms: AN 975, THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-
  5. Drug

    Onercept

    go.drugbank.com/drugs/DB06495
    Investigational

  6. Drug

    Atibuclimab

    go.drugbank.com/drugs/DB06546
    Investigational

    Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

  7. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  8. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  9. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...

  10. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.